Advertisement

Bulletin of Experimental Biology and Medicine

, Volume 158, Issue 4, pp 513–516 | Cite as

Dihydroquercetin Effects on the Morphology and Antioxidant/Prooxidant Balance of the Prostate in Rats with Sulpiride-Induced Benign Hyperplasia

  • T. G. Borovskaya
  • N. A. Krivova
  • O. B. Zaeva
  • T. I. Fomina
  • S. I. Kamalova
  • M. E. Poluektova
  • A. V. Vychuzhanina
  • Yu. A. Shchemerova
  • V. A. Grigor’eva
  • V. E. Goldberg
  • M. B. Plotnikov
Morphology and Pathomorphology

A course of dihydroquercetin (antioxidant) injections to 5-month-old Wistar rats with sulpiride-induced benign prostatic hyperplasia led to reduction of proliferative activity in the glandular structures and to attenuation of the inflammatory reaction in the tissue. Prostatic antioxidant/prooxidant balance returned to normal after the treatment.

Key Words

dihydroquercetin benign prostatic hyperplasia morphology antioxidant/prooxidant balance 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    T. G. Borovskaya, T. I. Fomina, L. A. Ermolaeva, et al., Bull. Exp. Biol. Med., 155, No. 1, 67-70 (2013).CrossRefPubMedGoogle Scholar
  2. 2.
    A. A. Volkov, O. V. Voronova, M. I. Petrichko, et al., Fundament. Issled., No. 12, Pt. 1, 36-39 (2012).Google Scholar
  3. 3.
    I. I. Gorpichenko, Yu. N. Gurzhenko, and V. V. Spiridonenko, Zdorov’e Muzhchiny, No. 1, 132-134 (2013).Google Scholar
  4. 4.
    V. I. Kirpatovskii, K. G. Marktchan, E. V. Frolova, and A. V. Kazachenko, Eksp. Klin. Urol., No. 2, 38-45 (2013).Google Scholar
  5. 5.
    Yu. V. Kudryavtsev and A. V. Sivkov, Eksp. Klin. Urol., No. 1, 18-22 (2010).Google Scholar
  6. 6.
    I. P. Khodchenkova, I. V. Zarubina, and P. D. Shabanov, Psikhofarmakol. Biol. Narkol., 5, No. 4, 1081-1085 (2005).Google Scholar
  7. 7.
    A. V. Chaika, A. D. Borodin, V. A. Chernous, and P. P. Verbovoi, Med.-Sots. Probl. Sem’i, 17, No. 1, 80-84 (2012).Google Scholar
  8. 8.
    N. Dhingra and D. Bhagwat, Ind. J. Pharmacol., 43, No. 1, 6-12 (2011).CrossRefGoogle Scholar
  9. 9.
    Frontiers in Antioxidant Research, Ed. H. V. Panglossi, New York (2006).Google Scholar
  10. 10.
    B. Halliwell, Cardiovasc. Res., 73, No. 2, 341-347 (2007).CrossRefPubMedGoogle Scholar
  11. 11.
    L. S. Marks, A. W. Partin, J. I. Epstein, et al., J. Urol., 163, No. 5, 1451-1456 (2000).CrossRefPubMedGoogle Scholar
  12. 12.
    C. H. Muller, T. K. Lee, and M. A. Montaño, Methods Mol. Biol., 927, 363-376 (2013).CrossRefPubMedGoogle Scholar
  13. 13.
    F. Van Coppenolle, C. Slomianny, F. Carpentier, et al., Am. J. Physiol. Endocrinol. Metab., 280, No. 1, E120-E129 (2001).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • T. G. Borovskaya
    • 1
  • N. A. Krivova
    • 2
  • O. B. Zaeva
    • 2
  • T. I. Fomina
    • 1
  • S. I. Kamalova
    • 1
  • M. E. Poluektova
    • 1
  • A. V. Vychuzhanina
    • 1
  • Yu. A. Shchemerova
    • 1
  • V. A. Grigor’eva
    • 1
  • V. E. Goldberg
    • 1
  • M. B. Plotnikov
    • 1
  1. 1.E. D. Goldberg Research Institute of PharmacologySiberian Division of the Russian Academy of Medical SciencesTomskRussia
  2. 2.Research Institute of Biology and BiophysicsTomsk State UniversityTomskRussia

Personalised recommendations